Market Overview

Top 4 NYSE Stocks In The Biotechnology Industry With The Highest Revenue Estimates

Related CRL
Lightning Round: Jim Cramer Advises His Viewers On Mallinckrodt, GoPro And More
Earnings Scheduled For November 9, 2017
Related EBS
Why Is Emergent Biosolutions (EBS) Up 3.9% Since the Last Earnings Report?
Anthrax And Government Contracts: PharmAthene And Altimmune Ahead Of Merger
FDA approves Emergent Biosolutions to manufacture ACAM2000 at Canton, Massachusetts facility (Seeking Alpha)

Below are the top biotechnology stocks on the NYSE in terms of revenue estimate for the current year.

Analysts expect Charles River Laboratories International (NYSE: CRL) to post revenue of $1.14 billion for the year ending December, 2012. Charles River Laboratories' trailing-twelve-month ROE is 17.83%.

Emergent BioSolutions (NYSE: EBS) is expected to report revenue of $286.38 million for the year ending December, 2012. Emergent BioSolutions' PEG ratio is 0.72.

Cambrex (NYSE: CBM) is likely to post revenue of $274.60 million in the year ending December, 2012. Cambrex's trailing-twelve-month operating margin is 12.83%.

ShangPharma (NYSE: SHP) may report revenue of $132.94 million in the year ending December, 2012. ShangPharma had $34.74 million in total cash for the recent quarter.

Posted-In: Biotechnology Industry Highest Revenue Estimates NYSETrading Ideas


Related Articles (CBM + CRL)

View Comments and Join the Discussion!

Partner Center